Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 50 results
Filters: First Letter Of Last Name is C  [Clear All Filters]
Found 50 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

C

Cachay ER, Frost SDW, Richman DD, Smith DM, Little SJ. "Herpes simplex virus type 2 infection does not influence viral dynamics during early HIV-1 infection." J. Infect. Dis.. 2007;195(9):1270-7.
Campbell TB, Smeaton LM, Kumarasamy N, et al. "Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings." PLoS Med.. 2012;9(8):e1001290.
Canter JA, Haas DW, Kallianpur AR, et al. "The mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral neuropathy." Pharmacogenomics J.. 2008;8(1):71-7.
Canter JA, Robbins GK, Selph D, et al. "African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy." J. Infect. Dis.. 2010;201(11):1703-7.
Cao YJun, Flexner CW, Dunaway S, et al. "Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteers." Antimicrob. Agents Chemother.. 2008;52(5):1630-4.
E Cardozo F, Andrade A, Mellors JW, Kuritzkes DR, Perelson AS, Ribeiro RM. "Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integration." PLoS Pathog.. 2017;13(7):e1006478.
Carlson JM, Brumme CJ, Martin E, et al. "Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1." J. Virol.. 2012;86(24):13202-16.
Carlton-Smith C, Holmes JA, Naggie S, et al. "IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR." J. Viral Hepat.. 2017.
Castillo-Mancilla JR, Aquilante CL, Wempe MF, et al. "Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342)." J. Antimicrob. Chemother.. 2016;71(6):1609-18.
Castillo-Mancilla JR, Cohn SE, Krishnan S, et al. "Minorities remain underrepresented in HIV/AIDS research despite access to clinical trials." HIV Clin Trials. 2014;15(1):14-26.
Celum C, Hong T, Cent A, et al. "Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study." J. Infect. Dis.. 2017;215(6):907-910.
Cespedes MS, Kerns SL, Holzman RS, McLaren PJ, Ostrer H, Aberg JA. "Genetic predictors of cervical dysplasia in African American HIV-infected women: ACTG DACS 268." HIV Clin Trials. 2013;14(6):292-302.
Cespedes MS, Aberg JA. "Neuropsychiatric complications of antiretroviral therapy." Drug Saf. 2006;29(10):865-74.
Cespedes MS, Kang M, Kojic EMilunka, et al. "Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1." Papillomavirus Res. 2018;6:15-21.
Chan ES, Landay AL, Brown TT, et al. "Differential CD4+ cell count increase and CD4+ :  CD8+ ratio normalization with maraviroc compared with tenofovir." AIDS. 2016;30(13):2091-7.
J Chang J, Woods M, Lindsay RJ, et al. "Higher expression of several interferon-stimulated genes in HIV-1-infected females after adjusting for the level of viral replication." J. Infect. Dis.. 2013;208(5):830-8.
Chen H, Clifford DB, Deng L, et al. "Peripheral neuropathy in ART-experienced patients: prevalence and risk factors." J. Neurovirol.. 2013;19(6):557-64.
Chew KW, Hua L, Bhattacharya D, et al. "The effect of hepatitis C virologic clearance on cardiovascular disease biomarkers in human immunodeficiency virus/hepatitis C virus coinfection." Open Forum Infect Dis. 2014;1(3):ofu104.
Chow FC, Wilson MR, Wu K, Ellis RJ, Bosch RJ, Linas BP. "Stroke incidence is highest in women and non-Hispanic blacks living with HIV in the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials cohort." AIDS. 2018;32(9):1125-1135.
Chow D, Chen H, Glesby MJ, et al. "Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients." AIDS. 2009;23(16):2133-41.
Chow FC, Makanjuola A, Wu K, et al. "Physical Activity Is Associated With Lower Odds of Cognitive Impairment in Women but Not Men Living With Human Immunodeficiency Virus Infection." J. Infect. Dis.. 2019;219(2):264-274.
Chung RT, Umbleja T, Chen JY, Andersen JW, Butt AA, Sherman KE. "Extended therapy with pegylated interferon and weight-based ribavirin for HCV-HIV coinfected patients." HIV Clin Trials. 2012;13(2):70-82.
Ciaranello AL, Lockman S, Freedberg KA, et al. "First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial." AIDS. 2011;25(4):479-92.
Cillo AR, Hilldorfer BB, Lalama CM, et al. "Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery." AIDS. 2015;29(16):2121-9.
Cillo AR, Krishnan S, McMahon DK, Mitsuyasu RT, Para MF, Mellors JW. "Impact of chemotherapy for HIV-1 related lymphoma on residual viremia and cellular HIV-1 DNA in patients on suppressive antiretroviral therapy." PLoS ONE. 2014;9(3):e92118.
Cimbro R, Vassena L, Arthos J, et al. "IL-7 induces expression and activation of integrin α4β7 promoting naive T-cell homing to the intestinal mucosa." Blood. 2012;120(13):2610-9.
Clark SA, Shulman NS, Bosch RJ, Mellors JW. "Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors." AIDS. 2006;20(7):981-4.
Clifford DB, Evans S, Yang Y, Acosta EP, Ribaudo H, Gulick RM. "Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s)." HIV Clin Trials. 2009;10(6):343-55.
Clifford DB, Smurzynski M, Park LS, et al. "Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients." Neurology. 2009;73(4):309-14.
Coban H, Robertson K, Smurzynski M, et al. "Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen." AIDS. 2017;31(11):1565-1571.

Pages